The uptake, nurturing and spreading of innovation in the NHS must become an integral part of all healthcare professionals in England.
News
Lilly pulls lymphoma drug enzastaurin after Phase III failure
Eli Lilly has suffered a setback in the lab after its lymphoma drug enzastaurin failed to met its survival goals in late-stage trials.
NHS hospital staffing levels dangerous, say nurses
A group of nursing and patient organisations in the UK are warning that staffing levels on a number of hospital wards in the NHS in England are “unsafe”.
Pfizer’s Remoxy review inflicts Pain on partner
Pfizer is weighing up whether to continue trying to get approval for Remoxy, a move which has had a disastrous effect on the stock prices of its two partners it has worked with on the abuse-resistant painkiller.
Actavis in talks to buy Warner Chilcott
Actavis and Warner Chilcott have announced that they are engaged in preliminary discussions regarding a possible merger.
Hepatitis C care “at risk” in the UK, say Roche
A new report by Roche and hep C patient groups says that more needs to be done to better that rate of treatment of hepatitis C in the UK.
IMS reports first decline in US drug spending “in 58 years”
Total spending on US medicines fell 3.5% on a real per-capita basis in 2012, and the use of healthcare services overall declined for the second consecutive year, according to a new study from the IMS Institute for Healthcare Informatics.
Second FDA thumbs-up for Novartis Ilaris
The US Food and Drug Administration has given the green light to Novartis’ Ilaris as a treatment for a serious form of childhood arthritis.
US green light for Warner Chilcott’s new contraceptive
US regulators have issued a green light for Warner Chilcott’s new oestrogen/progestin-based oral contraceptive, which is yet to be given an official trade name.
Amgen sets up China JV with Zhejiang Beta
Amgen is expanding its activities in China and establishing a joint venture with Zhejiang Beta Pharma Co to sell its colon cancer drug Vectibix.
GSK/Merck & Co cut HPV vaccine prices for poor
GlaxoSmithKline and Merck & Co have slashed the price on their respective human papillomavirus vaccines to protect millions of girls in the developing world against cervical cancer.
Canada: BC govt “halted drug safety studies to protect party donors”
In Canada, the Liberal provincial government of British Columbia “suddenly” halted drug safety studies which could have proved harmful to a number of drugmakers that have made “major” donations to the party, a law suit alleges.
England’s Cancer Drugs Fund widens; Scotland urged not to follow
While NHS England has added three new medicines to the national Cancer Drugs Fund, experts have urged the Scottish government not to establish such a Fund.
FDA agrees to review Merck & Co’s allergy pill
US regulators have agreed to review another of Merck & Co’s investigational, dissolvable allergy pills, this time to prevent allergic reactions to ragweed pollen.
Immigrants to pay for NHS care under new plans
Short-term migrants will be forced to pay for NHS care under a new bill being proposed by the UK Government.
